Adalimumab-associated multiple sclerosis

J Rheumatol. 2007 Jan;34(1):239-40; discussion 240.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / diagnosis
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use
  • Immunoglobulin gamma-Chains / adverse effects
  • Immunoglobulin gamma-Chains / therapeutic use
  • Multiple Sclerosis / chemically induced*
  • Multiple Sclerosis / diagnosis
  • Optic Neuritis / chemically induced
  • Optic Neuritis / diagnosis
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Immunoglobulin gamma-Chains
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Tumor Necrosis Factor-alpha
  • Ro 45-2081
  • Adalimumab
  • Etanercept